Litigation Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
✉ Email this page to a colleague
Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-07-18 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 7,579,473; 8,497,284; 8,877,776 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Exelixis, Inc. v. MSN Laboratories Private Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Exelixis, Inc. v. MSN Laboratories Private Limited (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-07-18 | 1 | Complaint | These notice letters alleged that U.S. Patent Nos. 7,579,473 and 8,497,284 were invalid, unenforceable… COMPLAINT FOR PATENT INFRINGEMENT 1. This is an action for patent infringement under…BACKGROUND 18. U.S. Patent No. 11,298,349 (“the ՚349 Patent”) (“Exhibit A”), entitled “Processes…2022. The ՚349 Patent will expire on February 10, 2032. The claims of the ՚349 Patent are valid, enforceable…inter alia, claim 3 of the ’349 Patent. 21. The ՚349 Patent has been listed in connection | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
